← Leaderboards
Benjamin A Belinka
Actinobac Biomed, Inc.
$2,250,118
Attributed
$2,250,118
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $905K · FY2012–16$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,250,118 · 2
By mechanism
R42$1,939,262 · 1
R41$310,856 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseKillingsLymphomaSpecificityMalignant - DescriptorLeukocytesIn VivoLeukotoxinMouse ModelSamplingPreclinical StudyNod/Scid MouseBiological ProductsB-Cell LymphomasCell DeathS LymphomaBiological Response Modifier TherapyAccountingDrug KineticsAntibodiesDrug TargetingEscherichia ColiCancer RelapseClinical Trials
Grant awards (5)
Targeting B-cell lymphoma with Leukothera-phase II$140,000
R42 · FY2016 · CA · contact PI
Targeting B-cell lymphoma with Leukothera-phase II$894,222
R42 · FY2015 · CA · contact PI
Targeting B-cell lymphoma with Leukothera-phase II$905,040
R42 · FY2014 · CA · contact PI
Targeting B-cell lymphoma with Leukothera$108,255
R41 · FY2013 · CA · contact PI
Targeting B-cell lymphoma with Leukothera$202,601
R41 · FY2012 · CA · contact PI